Dana Farber Cancer Center — Boston, Massachusetts

Dana Farber Cancer Center is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 83/100 (GOOD). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Center has participated in 24 clinical trials with 7 currently active.

Therapeutic areas: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC).

Sponsors: Novartis Pharmaceuticals, Artios Pharma Ltd, Georgetown University.

Sponsor Feasibility Report

Trust Score: 83/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Center?

Dana Farber Cancer Center has a Crixeo Trust Score of 83/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Center conducted?

Dana Farber Cancer Center has 24 clinical trials on record, with 7 currently active. Their work covers Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC).

Is Dana Farber Cancer Center accredited by Crixeo Health?

Yes — Dana Farber Cancer Center holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Dana Farber Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.